X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.fiercepharma.com/pharma/gsk-yanks-two-batches-its-asthma-blockbuster-nucala-taiwan-after-finding-glass-vial
https://www.gsk.com/en-gb/media/press-releases/china-national-medical-products-administration-accepts-regulatory-submission-for-nucala-mepolizumab-in-severe-eosinophilic-asthma/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125526
https://www.raps.org/news-and-articles/news-articles/2021/9/euro-roundup-chmp-recommends-drugs-from-biogen-and
https://www.pharmatimes.com/news/chmp_recommends_nucala_for_three_new_indications_1378441
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinions-recommending-approval-of-nucala-mepolizumab-in-three-additional-eosinophil-driven-diseases/
https://ca.gsk.com/en-ca/media/press-releases/2021/nucala-mepolizumab-approved-in-canada-as-the-first-and-only-biologic-treatment-for-adults-with-hypereosinophilic-syndrome/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761122
http://www.pharmatimes.com/news/nice_green_light_for_gsks_nucala_1362636
https://www.gsk.com/en-gb/media/press-releases/fda-accepts-gsk-s-filing-of-nucala-mepolizumab-for-use-in-chronic-rhinosinusitis-with-nasal-polyps/
https://www.gsk.com/en-gb/media/press-releases/fda-accepts-gsk-s-filing-of-nucala-mepolizumab-for-use-in-chronic-rhinosinusitis-with-nasal-polyps/
https://www.gsk.com/en-gb/media/press-releases/gsk-nucala-mepolizumab-filings-accepted-by-european-medicines-agency-for-three-additional-eosinophil-driven-diseases/
https://www.raps.org/news-and-articles/news-articles/2020/9/fda-roundup-nucala-fetroja-xeljanz
https://www.gsk.com/en-gb/media/press-releases/fda-approves-nucala-as-the-first-and-only-biologic-treatment-for-hypereosinophilic-syndrome-hes/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125526
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761122
https://www.prnewswire.com/news-releases/fda-approves-first-drug-to-treat-group-of-rare-blood-disorders-in-nearly-14-years-301138449.html
https://endpts.com/gsk-adds-to-its-trove-of-positive-data-for-multiple-myeloma-contender-as-rivals-continue-to-command-the-spotlight/
https://www.pharmaceutical-business-review.com/news/fda-grants-priority-review-of-nucala-for-patients-with-hypereosinophilic-syndrome/
https://www.fiercepharma.com/manufacturing/glaxosmithkline-awards-samsung-biologics-231-million-to-scale-up-manufacturing
http://www.pharmatimes.com/news/gsk_books_19_sales_growth_for_first_quarter_1339304
https://www.fiercepharma.com/pharma/glaxosmithkline-s-nucala-scores-dupixent-hunting-trial-win-nasal-polyps
https://endpts.com/gsks-asthma-biologic-nucala-is-one-step-closer-to-approval-in-key-chronic-rhinosinusitis-population/
https://www.fiercepharma.com/marketing/gsk-s-nucala-showdown-astrazeneca-s-fasenra-cuts-flares-rare-inflammatory-disease
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-2-2019-1570003052.pdf
https://www.fiercepharma.com/pharma/glaxosmithkline-s-nucala-cuts-severe-asthma-attacks-reassuring-interim-real-world-data
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761122
http://www.pharmatimes.com/news/nucala_receives_self-administration_eu_approval_1296183
http://www.pharmafile.com/news/525530/european-approval-two-new-delivery-formulations-gsks-nucala-severe-eosinophilic-asthma
https://www.fiercepharma.com/pharma/sanofi-and-regeneron-s-dupixent-scores-third-fda-approval-sinusitis-nasal-polyps
https://www.fiercepharma.com/pharma/astrazeneca-s-copd-triplet-breztri-rival-to-gsk-s-trelegy-nabs-first-nod-from-japan
https://www.fiercepharma.com/pharma/glaxosmithkline-s-nucala-scores-convenience-boost-at-home-dosing-options
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761122
https://www.fiercepharma.com/marketing/sanofi-and-regeneron-delves-deep-uncontrolled-asthma-digital-awareness-campaign
https://www.fiercepharma.com/pharma/novartis-xolair-looking-to-hold-blockbuster-status-positive-sinusitis-data
https://www.fiercepharma.com/pharma/az-s-fasenra-offers-severe-asthma-patients-two-years-benefits-analysis
http://www.pharmatimes.com/news/nice_recommends_fasenra_injection_as_asthma_alternative_1273752
https://scrip.pharmaintelligence.informa.com/SC124179/ICER-On-Asthma-Biologics-5079-Price-Discounts-Needed-To-Meet-Value-Assessment-Metrics
https://www.fiercepharma.com/marketing/roche-novartis-grab-fda-ok-for-new-version-aging-blockbuster-xolair
https://www.fiercepharma.com/marketing/fda-deals-a-blow-to-glaxosmithkline-s-post-advair-hopes-nucala-copd-rebuff
https://www.reuters.com/article/us-gsk-nucala-ema/gsk-says-u-s-fda-wants-more-information-on-pulmonary-drug-idUSKCN1LN2PA
https://www.biopharmadive.com/news/ec-approves-gsks-nucala-for-kids-with-severe-asthma/531403/
http://www.pharmatimes.com/news/gsks_nucala_approved_for_younger_asthma_patients_1250722
https://www.fiercepharma.com/pharma/astrazeneca-s-new-launches-shine-q2-as-it-inches-toward-turnaround
Market Place
Share 
